SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection.

Dowell, AC; Butler, MS; Jinks, E; Tut, G; Lancaster, T; Sylla, P; Begum, J; Bruton, R; Pearce, H; Verma, K; et al. Dowell, AC; Butler, MS; Jinks, E; Tut, G; Lancaster, T; Sylla, P; Begum, J; Bruton, R; Pearce, H; Verma, K; Logan, N; Tyson, G; Spalkova, E; Margielewska-Davies, S; Taylor, GS; Syrimi, E; Baawuah, F; Beckmann, J; Okike, IO; Ahmad, S; Garstang, J; Brent, AJ; Brent, B; Ireland, G; Aiano, F; Amin-Chowdhury, Z; Jones, S; Borrow, R; Linley, E; Wright, J; Azad, R; Waiblinger, D; Davis, C; Thomson, EC; Palmarini, M; Willett, BJ; Barclay, WS; Poh, J; Amirthalingam, G; Brown, KE; Ramsay, ME; Zuo, J; Moss, P; Ladhani, S (2022) Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection. Nat Immunol, 23 (1). pp. 40-49. ISSN 1529-2916 https://doi.org/10.1038/s41590-021-01089-8
SGUL Authors: Ladhani, Shamez Nizarali

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview
[img]
Preview
PDF (Supplementary Information) Published Version
Available under License Creative Commons Attribution.

Download (573kB) | Preview
[img]
Preview
PDF (Peer Review Information) Published Version
Available under License Creative Commons Attribution.

Download (341kB) | Preview

Abstract

SARS-CoV-2 infection is generally mild or asymptomatic in children but a biological basis for this outcome is unclear. Here we compare antibody and cellular immunity in children (aged 3-11 years) and adults. Antibody responses against spike protein were high in children and seroconversion boosted responses against seasonal Beta-coronaviruses through cross-recognition of the S2 domain. Neutralization of viral variants was comparable between children and adults. Spike-specific T cell responses were more than twice as high in children and were also detected in many seronegative children, indicating pre-existing cross-reactive responses to seasonal coronaviruses. Importantly, children retained antibody and cellular responses 6 months after infection, whereas relative waning occurred in adults. Spike-specific responses were also broadly stable beyond 12 months. Therefore, children generate robust, cross-reactive and sustained immune responses to SARS-CoV-2 with focused specificity for the spike protein. These findings provide insight into the relative clinical protection that occurs in most children and might help to guide the design of pediatric vaccination regimens.

Item Type: Article
Additional Information: Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. © The Author(s) 2021
Keywords: Immunology, 1107 Immunology
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Nat Immunol
ISSN: 1529-2916
Language: eng
Dates:
DateEvent
January 2022Published
22 December 2021Published Online
3 November 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
MC UU 1201412Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
MR/W005611/1Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
PubMed ID: 34937928
Web of Science ID: WOS:000733875700001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/114013
Publisher's version: https://doi.org/10.1038/s41590-021-01089-8

Actions (login required)

Edit Item Edit Item